Atlas Venture Life Science Advisors, LLC Q2 2024 Filing
Filed August 9, 2024
Portfolio Value
$949.6B
Holdings
15
Report Date
Q2 2024
Filing Type
13F-HR
All Holdings (15 positions)
| # | Stock | Shares | Value | % Portfolio | Type |
|---|---|---|---|---|---|
| 1 | DYNDyne Therapeutics, Inc. | 8,020,136 | $283.0B | 29.80% | |
| 2 | KYMRKymera Therapeutics, Inc. | 5,350,422 | $159.7B | 16.82% | |
| 3 | THRDThird Harmonic Bio, Inc. | 10,907,859 | $141.8B | 14.93% | |
| 4 | IRONDisc Medicine, Inc. | 2,509,456 | $113.1B | 11.91% | |
| 5 | DAWNDay One Biopharmaceuticals, Inc. | 6,430,257 | $88.6B | 9.33% | |
| 6 | KRROKorro Bio, Inc. | 1,137,149 | $38.5B | 4.06% | |
| 7 | QTTBQ32 Bio, Inc. | 2,092,106 | $37.6B | 3.95% | |
| 8 | GBIOGBXGeneration Bio, Co. | 8,279,484 | $23.3B | 2.46% | |
| 9 | VIGLVigil Neuroscience, Inc. | 5,836,874 | $23.3B | 2.46% | |
| 10 | REPLReplimune Group, Inc. | 2,098,300 | $18.9B | 1.99% | |
| 11 | —Ikena Oncology, Inc. | 5,018,178 | $8.3B | 0.87% | |
| 12 | TECXTectonic Therapeutics, Inc. | 378,447 | $6.2B | 0.66% | |
| 13 | DNTHDianthus Therapeutics, Inc. | 136,979 | $3.5B | 0.37% | |
| 14 | AVTEAerovate Therapeutics, Inc. | 1,799,232 | $3.0B | 0.31% | |
| 15 | SPROSpero Therapeutics, Inc. | 535,336 | $695.9M | 0.07% |